Oslomed – Clinical Trial Site Organization

Diabetes & Obesity

Diabetes and obesity are interconnected global health challenges affecting hundreds of millions of people worldwide. These metabolic disorders significantly impact quality of life, cardiovascular health, and overall mortality, highlighting the need for innovative therapeutic approaches and comprehensive clinical research.

Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. The condition leads to persistent hyperglycemia and affects multiple organ systems. T2DM most commonly occurs in adults over 45 years of age, though increasing rates are observed in younger populations and adolescents, particularly among obese individuals. The disease is closely linked to obesity, as adipose tissue promotes insulin resistance through inflammatory mechanisms and the release of free fatty acids.

Obesity

OObesity is a chronic, multisystem disease defined by excessive adipose tissue accumulation (BMI ≥30 kg/m²) that impairs health and quality of life. It is a major contributor to type 2 diabetes, cardiovascular disease, metabolic syndrome, certain cancers, and musculoskeletal disorders. The condition results from complex interactions among genetic predisposition, environmental factors, dietary habits, physical inactivity, and neuroendocrine regulation.

Metabolic Syndrome

Metabolic syndrome is a cluster of interconnected cardiometabolic risk factors that significantly increase the risk of developing type 2 diabetes, cardiovascular disease, and stroke. The syndrome is diagnosed when at least three of the following criteria are met: abdominal obesity (increased waist circumference), elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose or evidence of insulin resistance.

Weight Management & Prediabetes

Weight management is a critical preventive strategy for individuals at risk of developing type 2 diabetes and cardiovascular disease. Prediabetes, characterized by impaired fasting glucose (100–125 mg/dL) or impaired glucose tolerance (HbA1c 5.7–6.4%), affects a substantial portion of adults and represents a key window of opportunity for intervention. Without intervention, 5–10% of individuals with prediabetes progress to diabetes each year

Interested in Collaboration?

Are you a sponsor or research organization planning a diabetes or obesity clinical trial in Poland? Contact our clinical trials team to discuss feasibility and site capabilities.

Back to Therapeutic Areas